Abstract

The Contractor will receive, maintain, and expand cell lines and virus for use in testing experimental agents against the HIV virus, prepare experimental agents for testing, test for antiviral activity of 10,000 agents per year in accordance with NCI approved protocol for large scale HIV Screening, and submit testing results as specified. The Contractor will also perform confirmation testing on approximately 80 experimental agents per year identified as active in the primary screen, conduct more detailed testing of 30 to 40 experimental agents per year, and maintain a pathogen free mouse facility for testing of experimental agents in a small animal model system.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM037818-000
Application #
2300584
Study Section
Project Start
1993-04-01
Project End
1998-01-31
Budget Start
1993-04-01
Budget End
1994-01-31
Support Year
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205

  Publications

Buckheit Jr, R W; White, E L; Fliakas-Boltz, V et al. (1999) Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 43:1827-34
Buckheit Jr, R W; Hollingshead, M; Stinson, S et al. (1997) Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res Hum Retroviruses 13:789-96
Kinjerski, T L; Buckheit Jr, R W (1997) The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses. Antiviral Res 33:109-15
Buckheit Jr, R W; Snow, M J; Fliakas-Boltz, V et al. (1997) Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 41:831-7
Cushman, M; Golebiewski, W M; Graham, L et al. (1996) Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors. J Med Chem 39:3217-27
Halliday, S M; Lackman-Smith, C; Bader, J P et al. (1996) Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene. Antiviral Res 33:41-53
Buckheit Jr, R W; Kinjerski, T L; Fliakas-Boltz, V et al. (1995) Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob Agents Chemother 39:2718-27
Buckheit Jr, R W; Fliakas-Boltz, V; Decker, W D et al. (1995) Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res 26:117-32
Clanton, D J; Buckheit Jr, R W; Terpening, S J et al. (1995) Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res 27:335-54
Yang, S S; Fliakas-Boltz, V; Bader, J P et al. (1995) Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Leukemia 9 Suppl 1:S75-85

Showing the most recent 10 out of 13 publications